FDA Seeks Approval to Track Real Cost Anti-Smoking Campaign Progress
Published Date: 7/3/2025
Notice
Summary
The FDA is asking for approval to keep collecting info for the Real Cost Monthly Implementation Assessment, which helps track how well their anti-smoking efforts are working. This affects people involved in the program and means they’ll keep sharing data regularly. The review process is underway, so expect updates soon, but no big costs or changes for most folks right now.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA Continues Anti‑Smoking Data Collection
The FDA is keeping its Real Cost Monthly Implementation Assessment to track how well anti‑smoking efforts are working. People involved in that program will continue to share data on a regular basis while the Office of Management and Budget reviews the information collection. The notice says the review is underway and that there are no big costs or changes for most people right now.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2025-12419, Agency Information Collection Activities; Proposed Collection; Comment Request; Center for Devices and Radiological Health Appeals Processes
The FDA wants your thoughts on how it collects info about appeals for medical devices and radiation safety. This affects companies and people who deal with device approvals and complaints. They’re asking for comments over the next 60 days to make sure the process is clear and fair, with no extra costs or delays.
Next: 2025-12421, General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of Public Docket; Request for Comments-Dermal Fillers
The FDA is hosting a public meeting with experts to talk about dermal fillers, the stuff used in cosmetic treatments like smoothing wrinkles. They want to hear from everyone—doctors, patients, and companies—before making any decisions. This is your chance to share thoughts and help shape future rules, with no cost to join and plenty of time to get involved!